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abstract
PURPOSE A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically
inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of
disrupting the tumor microenvironment.
PATIENTS AND METHODS A multicenter, open-label, repeated-dose, phase I study was conducted to assess the
safety, tolerability, and pharmacokinetics of MP0250 in 45 patients with advanced solid tumors. In the dose-
escalation part, 24 patients received MP0250 as a 3-hour infusion once every 2 weeks at five different dose
levels (0.5-12mg/kg). Once themaximum tolerated dose (MTD) was established, 21 patients were treated with a
1-hour infusion (n5 13, 8 mg/kg, once every 2 weeks and n5 8, 12 mg/kg, once every 3 weeks) of MP0250 in
the dose confirmation cohorts.
RESULTS In the dose-escalation cohort, patients treated with 12 mg/kg MP0250 once every 2 weeks experi-
enced dose-limiting toxicities. Therefore, MTDwas 8mg/kg once every 2 weeks or 12mg/kg once every 3 weeks.
The most common adverse events (AEs) were hypertension (69%), proteinuria (51%), and diarrhea and nausea
(both 36%); hypoalbuminemia was reported in 24% of patients. Most AEs were consistent with inhibition of the
VEGF and HGF pathways. Exposure was dose-proportional and sustained throughout the dosing period for all
patients (up to 15 months). The half-life was about 2 weeks. Signs of single-agent antitumor activity were
observed: 1 unconfirmed partial response with a time to progression of 23 weeks and 24 patients with stable
disease, with the longest duration of 72 weeks and a median duration of 18 weeks.
CONCLUSION MP0250 is a first-in-class DARPin drug candidate with suitable tolerability and appropriate
pharmacokinetic properties for further development in combination with other anticancer therapies.
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INTRODUCTION
We report here the first-in-human study of MP0250, a
DARPin drug candidate and novel biologic that spe-
cifically and simultaneously binds to and inhibits
vascular endothelial growth factor (VEGF) and hepa-
tocyte growth factor (HGF).1
DARPin molecules are a class of small, highly specific
binding proteins that can be easily assembled in a
multispecific format; this is especially attractive for
oncology drug development where simultaneous tar-
geting of several pathways could be advantageous.
Several other DARPin molecules are in the clinical and
preclinical development stage.
The rationale for concomitant targeting of the VEGF-
and HGF-driven signaling pathways is to produce
greater disruption of the tumor cell-supporting micro-
environment and thus overcome the clinical short-
comings of mono-targeted VEGF and HGF inhibitors.2-9
MP0250 is a tri-specific molecule with individual
domains binding VEGF and HGF with picomolar af-
finity and two domains binding human serum albumin
(HSA) to increase its plasma half-life (Fig 1). Pre-
clinical studies have shown MP0250 to have greater
effects on tumor growth and angiogenesis than indi-
vidual VEGF- and HGF-blocking DARPin molecules
and also demonstrated potentiation of the antitumor
activities of cytotoxic and immunomodulatory
agents.10 In addition, there is support from the liter-
ature for the potential to overcome treatment resis-
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This manuscript summarizes the phase I experience with
MP0250 in patients with cancer and thus constitutes the
basis of MP0250 clinical development as well as the de-
velopment of other systemically administered DARPin
molecules.
PATIENTS AND METHODS
Study Design and Treatment
This was a multicenter, open-label, phase I, dose-
escalation, and expansion study of intravenously
administered MP0250 (ClinicalTrials.gov identifier:
NCT02194426). The primary objectives were to determine
the maximum tolerated dose (MTD) and to assess dose-
limiting toxicities (DLTs), pharmacokinetics (PKs), safety,
and tolerability. The secondary objective was to charac-
terize the immunogenicity of MP0250. Exploratory objec-
tives included assessment of biomarkers and antitumor
activity of MP0250.
The dose-escalation phase followed a traditional 3 1 3
study design including five dose cohorts (C1-C5) of 0.5,
1.5, 4, 8, and 12 mg/kg of MP0250 administered over a
3-hour infusion once every 2 weeks. The MTD was defined
as the dose below the dose level that produces DLTs
in $ 33% of patients. Once the MTD was established, two
dose expansion cohorts were opened to further charac-
terize the safety and biological activity of the selected dose.
In the expansion cohorts, MP0250 was administered as a
1-hour infusion once every 2 weeks (cohort 6, C6, 13
patients at 8 mg/kg) or once every 3 weeks (cohort 7, C7, 8
patients at 12 mg/kg). The switch from once every 2 weeks
to once every 3 weeks was supported by emerging PK data,
and the infusion duration was reduced from 3 hours to 1
hour for patient convenience and to align with future once-
every-3-week combination studies. Patients who benefited
from treatment could continue treatment until tumor pro-
gression, unacceptable toxicity, or withdrawal from this
study.
A DLT was defined as any drug-related adverse event (AE)
meeting DLT criteria (provided in the Data Supplement,
online only) that occurred from the time of first dose until
completion of the DLT period (defined as 1 week after the
third infusion in the once every 2 weeks schedule and
1 week after the second infusion in the once every 3 weeks
CONTEXT
Key Objective
DARPin molecules are a class of small, highly specific binding proteins that can be easily assembled to bind multiple
molecular targets. MP0250 is a tri-specific molecule with individual domains binding vascular endothelial growth factor
(VEGF), hepatocyte growth factor (HGF), and human serum albumin to increase its plasma half-life. This first-in-human
study of intravenously administered MP0250 sought to determine the maximum tolerated dose (MTD) and assess its
dose-limiting toxicities, pharmacokinetics, safety, and tolerability.
Knowledge Generated
The MTD of MP0250 was 8 mg/kg once every 2 weeks or 12 mg/kg once every 3 weeks. Drug half-life was about 2 weeks.
Most adverse events were consistent with inhibition of the VEGF and HGF pathways, most commonly hypertension,
proteinuria, nausea, diarrhea, and hypoalbuminemia. Single-agent antitumor activity was observed, including 1 patient
with an unconfirmed partial response.
Relevance
MP0250 is a first-in-class DARPin drug candidate with a tolerability profile and pharmacokinetic properties, making it
suitable for further development in combination with other anticancer therapies.
HSA HGF VEGF HSA
FIG 1. Structure of MP0250. HGF, hepatocyte growth factor; HSA, human serum albumin; VEGF, vascular endothelial growth factor.
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schedule). A dose-escalation committee decided on dose
escalation after all patients in a given cohort had completed
the DLT period.
This study was approved by the ethics committees of
participating institutions and appropriate regulatory au-
thorities. All patients provided written informed consent.
This study was conducted in compliance with the Decla-
ration of Helsinki and guidelines for International Council
for Harmonisation Good Clinical Practice.
Eligibility
Patients were at least 18 years old with advanced or
metastatic solid tumor refractory to at least one line of prior
standard treatment or for which no curative therapy was
available. Patients had measurable or evaluable disease
per RECIST version 1.1 and an Eastern Cooperative On-
cology Group (ECOG) performance status of zero or one.
Safety Assessments
Routine clinical and laboratory assessments, including
hematology, clinical chemistry, urinalysis, vital signs, and
electrocardiography, were conducted at baseline and
regularly throughout this study until up to 10 weeks after the
last MP0250 administration.
AEs were continuously reported and coded using Medical
Dictionary for Regulatory Activities version 17.0 terminol-
ogy. AE intensity was graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03.
PKs, Antidrug Antibodies, and Pharmacodynamics
Plasma samples for PKs, antidrug antibody (ADA), and
cytokine assessment were collected at predefined time
intervals. More detailed information is given in the Data
Supplement.
Antitumor Activity
Radiologic tumor response assessments were performed
by computed tomography or magnetic resonance imaging
scans at screening and at 8-week intervals thereafter.
Tumor responses were assessed using RECIST v1.1.
Statistical Analyses
This was an open-label phase I study. Sample sizes of at
least 15 patients in the dose-escalation part (ie, at least
three patients for the five doses planned) and 16 patients in
the expansion part (eight per dose group) were considered
sufficient to adequately address the objectives of this study.
All patients exposed to MP0250 were included in the safety
analysis, and all patients for whom at least one PK,
pharmacodynamic (PD), or antitumor activity parameter
could be reasonably assessed were evaluated for these
parameters. All data were descriptively summarized.




Twenty-four patients were enrolled in the dose-escalation
phase, and 21 patients were enrolled in the expansion
phase of this study. Patient characteristics of all 45 patients
are summarized in Table 1. The most frequent tumor
entities were colorectal cancer (31%) and ovarian cancer
(13%). The ECOG performance status was 0 in 32 patients
(71%) and 1 in 13 patients (29%). Twelve patients (27%)
received previous anti-VEGF treatment. All patients com-
pleted at least one infusion of MP0250 (median, four in-
fusions; range, 1-31 infusions).
MTD and DLT Evaluation
Treatment cohorts and DLTs are listed in Table 2. During
the dose-escalation phase, four patients experienced DLTs.
No DLTs were observed in the first two dose cohorts (0.5
and 1.5 mg/kg). In cohort 3 (4 mg/kg), one DLT occurred
and this cohort was expanded to a total of six patients with
no additional DLTs. In the next dose cohort (8 mg/kg), no
DLT was reported in the first three treated patients. In
cohort 5 (12 mg/kg), one of the three patients experienced
two DLTs, leading to expansion of that cohort by two pa-
tients. After the second patient in this cohort experienced a
DLT, the dose of the remaining patients was reduced to
8 mg/kg (two patients). Three more patients were enrolled
at 8 mg/kg (cohort 4), of which one patient experienced
TABLE 1. Patient Demographics and Baseline Tumor Characteristics
Characteristic All Patients (N5 45)








Colorectal cancer 14 (31)
Ovarian cancer 6 (13)




Head and neck cancer 3 (7)
Clear cell renal carcinoma 2 (4)
Spindle cell sarcoma 2 (4)
Others 9 (20)
Unknown primary 3 (7)
NOTE. Others: cervical, anal, mesothelioma, gallbladder,
esophagus, melanoma, neuroectodermal, endometrial sarcoma, and
endometrial carcinoma.
Abbreviation: ECOG, Eastern Cooperative Oncology Group
Journal of Clinical Oncology 3
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three DLTs. As nomore than 17% of patients experienced a
DLT at this dose level, the administration of 8 mg/kg once
every 2 weeks (and its dose intensity equivalent of 12mg/kg
once every 3 weeks) was established as MTD for MP0250
monotherapy in oncology patients and consequently used
in the expansion phase. In the dose expansion phase, two
of the 21 patients experienced DLTs.
Safety
Treatment-emergent AEs that were reported in more than
10% of patients are shown in Table 3. The most frequent
AEs were hypertension (69% of patients), proteinuria
(51%), and diarrhea and nausea (both 36%). Hypo-
albuminemia was reported in 24% of patients. Proteinuria
was reported at a MP0250 dose $ 8 mg/kg once every
2 weeks, while hypertension was observed at all tested dose
levels. The majority of AEs were of grade 1 or 2. An infusion-
related reaction was reported in one patient.
Grade 3 hypertension and proteinuria were reported in 16
and three patients (36% and 7%), respectively. The median
onset was at day 21 for hypertension and day 62 for pro-
teinuria. Median durations of the AEs were 8 days and
29 days for hypertension and proteinuria, respectively. No
correlation between previous anti-VEGF treatment and the
occurrence of these AEs was found. Treatment was dis-
continued due to proteinuria in six patients (13%), including
one patient experiencing concomitant grade 2 hypertension.
Eleven patients (24%) experienced serious adverse reactions,
as shown in the Data Supplement; those reported by more
than one patient included nephrotic syndrome (four patients,
9%) and pulmonary embolism (three patients, 7%). Ten
patients died during the treatment phase of this study, nine
of them due to disease progression. The tenth patient died
from cardiac failure where MP0250 could not be completely
excluded as being a contributing factor; however, this patient
had several preexisting cardiac risk factors: significant ex-
posure to anthracycline chemotherapy and prior mediastinal
irradiation, hypertension, left bundle branch block, and
dyslipidemia. Later, atrial fibrillation was also reported as an
AE (CTCAE severity grade 2), and the patient died 65 days
after the first and last doses of MP0250. This event was
judged retrospectively to be possibly related to MP0250
administration.
Treatment was discontinued due to AEs in 14 patients
(31%). The most frequent AEs leading to treatment dis-
continuation were nephrotic syndrome (four patients, 9%),
malignant neoplasm progression (two patients, 4%), and
proteinuria (two patients, 4%).
PKs and ADAs
PK parameters are shown in Table 4, and median
concentration-time profiles of cohorts in the dose-escalation
part are depicted in Figure 2. After MP0250 infusion, the
maximum concentration (Cmax) was followed by a decline of
serum concentrations in a roughly monoexponential man-
ner. The exposure-related parameters Cmax and area under
the curve (AUC) increased in proportion to the dose. The
estimated values of clearance, volume of distribution, and
half-life were similar between dose levels, suggesting a linear
PK of MP0250 in the dose range from 0.5 to 12 mg/kg. The
estimated ranges of the geometric means of clearance and
volume of distribution in the steady state were 0.070-0.146
mL/h/kg and 27.5-59.9 mL/kg, respectively.
Following multiple-dose administration, MP0250 accumu-
lated in the once-every-2-weeks and once-every-3-weeks
dosing regimens. Steady-state conditions were established
after approximately 6 weeks, corresponding to infusion 4
TABLE 2. Dose-Limiting Toxicities
DLTs, n (%) CTCAE Grade



















Acute left ventricular failure 3 — — 1 (17) — — — — — 1 (2)
Blood creatinine increase 2 — — — 1 (14) — — — — 1 (2)
Blood urea increase 3 — — — 1 (14) — — — — 1 (2)
Gastrointestinal hemorrhage 3 — — — — 1 (33) — — — 1 (2)
Hypertension 3 — — — — 1 (33) — — — 1 (2)
Nephrotic syndrome 3 — — — — 1 (33) — 1 (8) 1 (13) 3 (7)
Thrombotic microangiopathy 4 — — — 1 (14) — — — — 1 (2)
Total number of patientsd — — 1 (17) 1 (14) 2 (67) — 1 (8) 1 (13) 6 (13)
NOTE. Unless indicated otherwise, infusions were administered over 3 hours every 2 weeks.
Abbreviations: C, cohort; CTCAE, Common Terminology Criteria for Adverse Events; DLTs, dose-limiting toxicities.
aFirst infusion 12 mg/kg and subsequent infusions 8 mg/kg.
bAdministration over 1 hour.
cOnce-every-3-weeks dosing schedule.
dOne patient may experience more than 1 DLT.
4 © 2020 by American Society of Clinical Oncology
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TABLE 3. Common Treatment-Emergent Adverse Events (in at Least 10% of Patients, Highest Grade Per Patient)
MedDRA System
Organ Class




















b,c n 5 8
Total, N
5 45
GI disorders Abdominal pain All — — 1 (17) 2 (29) 1 (33) — 2 (15) 1 (13) 7 (16)
Constipation All — — 1 (17) — 1 (33) — 2 (15) 2 (25) 6 (16)
Diarrhea All 1 (33) 2 (67) 2 (33) 3 (43) 1 (33) 1 (50) 3 (23) 3 (38) 16 (36)
3 — — — — — — 1 (8) — 1 (2)
Nausea All — 1 (33) 3 (50) 3 (43) — — 5 (39) 2 (25) 14 (31)
Vomiting All 1 (33) — 2 (33) 4 (57) — — 3 (23) 2 (25) 12 (27)
General disorders Asthenia All — — — 1 (14) — — 1 (8) 3 (38) 5 (11)
Fatigue All 1 (33) 2 (67) 1 (17) 4 (57) 2 (67) 1 (50) 2 (15) 1 (13) 14 (31)
3 — — — 1 (14) — — — — 1 (2)






All — — 1 (17) — 1 (33) — 2 (15) 2 (25) 6 (13)
3 — — 1 (17) — — — — — 1 (2)
Blood CPK increase All — — — 1 (14) — 1 (50) 3 (23) 1 (13) 6 (13)
3 — — — — — — 1 (8) — 1 (2)
Blood creatinine
increase
All — — 2 (33) 2 (29) — — 3 (23) — 7 (16)
Platelet count decrease All — — 1 (17) 4 (57) — — 3 (23) — 8 (18)
4 — — 1 (17) — — — — — 1 (2)
Metabolism and
nutrition
Decreased appetite All 1 (33) — 2 (33) 1 (14) 1 (33) — 4 (31) 3 (38) 12 (27)
Hypoalbuminemia All — — 1 (17) 2 (29) — 1 (50) 4 (31) 3 (38) 11 (24)
3 — — — — — — 1 (8) — 1 (2)
Musculoskeletal Back pain All 1 (33) — 1 (17) 1 (14) 1 (33) — 2 (15) 2 (25) 8 (18)
Neoplasms Malignant neoplasm
progression
All — — 3 (50) 1 (14) 1 (33) — 2 (15) 7 (16)
3 — — 1 (17) — — — — 5 (11)
5 — — 2 (33) 1 (14) 1 (33) — 1 (8) (2)
Nervous system
disorders
Headache All — — 1 (17) 1 (14) 1 (33) 1 (50) 2 (15) 3 (38) 9 (20)
Renal urinary
disorders
Proteinuria All — — — 5 (71) 1 (33) 2 (100) 9 (69) 6 (75) 23 (51)
3 — — — — 1 (33) 1 (50) 1 (78) — 3 (7)
Respiratory Cough All 1 (33) 1 (33) 1 (17) 3 (43) — 1 (50) 3 (23) 1 (13) 11 (24)
Dyspnea All — 1 (33) 1 (17) 2 (29) 1 (33) — 1 (8) — 6 (13)
5 — — — — 1 (33) — 1 (8) — 2 (4)
Vascular disorders Hypertension All 1 (33) 1 (33) 4 (67) 6 (86) 2 (67) 2 (100) 9 (69) 6 (75) 31 (69)
3 — 1 (33) 3 (50) 3 (43) 1 (33) 1 (50) 5 (39) 2 (25) 16 (36)
NOTE. Unless indicated otherwise, infusions were administered over 3 hours every 2 weeks.
Abbreviations: C, cohort; CPK, creatine phosphokinase; CTCAE, Common Terminology Criteria for Adverse Events; DLTs, dose-limiting toxicities; n, number
of cases; N, number of patients per cohort; MedDRA, Medical Dictionary for Regulatory Activities.
aFirst infusion 12 mg/kg and subsequent infusions 8 mg/kg.
bAdministration over 1 hour.
cEvery 3-week dosing schedule.
Journal of Clinical Oncology 5
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TABLE 4. Pharmacokinetic Parameters of MP0250
PK Parameter Infusion Number
Cohort (Dose, mg/kg MP0250)
C1 (0.5) C2 (1.5) C3 (4) C4 (8) C5 (12) C6 (8)a C7 (12 mg/kg)a,b
1 4 1 4 1 4 1 4 1 4 1 4 1 3
Cmax (mg/mL) n 3 3 3 2 6 5 7 3 5 12 6 8 5
Geometric mean 12.6 23.2 53.4 78.4 124 232 280 419 414 n.d. 246 481 379 498
Coefficient of
variation (%)
6.4 31 24 11 14 13 29 4.6 22 34 13 39 36
Cmin (mg/mL) n 3 3 3 1 5 4 6 3 5 10 6 7 4
Geometric mean 3.97 8.53 20.6 29.8 46.6 119 101 188 102 n.d. 81.9 206 89.9 143
Coefficient of
variation (%)
13 10 9.9 29 31 37 16 25 28 20 47 47
tmax (h) n 3 3 3 2 6 5 7 3 5 12 6 8 5
Median 4.0 0.15 0.75 2.0 1.2 0.08 24 0.10 3.9 n.d. 3.9 4.1 2 2.3
Minimum-
maximum
2.2-8.0 0.03-2.3 0.42-4.5 0.08-4.0 0.12-4.1 0.08-4.0 0.07-71 0.03-3.8 2.0-120 0.03-71 0.18-166 0.07-166 0.13-8.0
AUCtau
(mg*h/mL)
n 3 3 3 1 5 4 6 3 5 10 6 7 4
Geometric mean 2,370 4,530 10,400 17,500 24,900 56,500 50,100 80,700 59,600 n.d. 48,800 114,000 81,900 130,000
Coefficient of
variation (%)
6.5 21 4.8 17 28 33 4.2 8.8 27 14 48 45
AUCinf
(mg*h/mL)
n 3 3 3 1 6 3 4 2 4 9 5 4 4
Geometric mean 3,760 7,610 18,900 27,200 42,800 99,400 82,300 154,000 87,300 n.d. 71,900 207,000 102,000 201,000
Coefficient of
variation (%)
13 12 10 22.8 76 29 23 15 27 26 21 46
CL (mL/h/kg) n 3 3 3 1 6 4 4 3 4 9 6 4 4
Geometric mean 0.146 0.120 0.0874 0.0945 0.0950 0.0707 0.097 0.100 0.137 n.d. 0.113 0.0703 0.118 0.0923
Coefficient of
variation (%)
13 23 10 20 28 31 4.3 15 27 14 21 45
VSS (mL/kg) n 3 3 3 1 5 2 4 2 4 8 5 4 3
Geometric mean 49.7 42.8 36.0 29.5 35.9 53.7 40.9 40.9 41.0 n.d. 39.6 27.5 59.9 49.0
Coefficient of
variation (%)
3.4 40 9.7 19 47 43 28 10 24 33 22 73
AR 2 Cmax n 3 2 5 3 6 5
Mean 1.93 1.58 1.90 1.24 n.d. 1.64 1.43
Standard
deviation
0.74 0.29 0.29 0.15 0.49 0.50
AR 2 AUC n 3 1 4 3 6 4
Mean 1.93 1.67 2.32 1.38 n.d. 2.08 1.74
Standard
deviation
0.32 0.47 0.25 0.49 0.26
t1/2 (h) n 3 3 3 1 6 3 4 2 4 9 5 4 4
Median 252 260 293 225 250 244 281 276 215 n.d. 265 279 374 356
Minimum-
maximum
210-267 217-268 237-331 222-355 224-771 229-401 222-329 176-252 173-347 194-408 329-384 226-430
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TABLE 4. Pharmacokinetic Parameters of MP0250 (continued)
PK Parameter Infusion Number
Cohort (Dose, mg/kg MP0250)
C1 (0.5) C2 (1.5) C3 (4) C4 (8) C5 (12) C6 (8)a C7 (12 mg/kg)a,b
1 4 1 4 1 4 1 4 1 4 1 4 1 3
t1/2 2
effective (h)
n 3 1 4 3 6 4
Median 289 255 425 212 n.d. 388 389
Minimum-
maximum




n 2 3 3 5 2 8 2
Median 279 285 324 421 398 321 592
Minimum-
maximum
255-303 214-340 284-405 369-628 311-486 177-2000 411-773
NOTE. Unless indicated otherwise, infusions were administered over 3 hours every 2 weeks. Bold indicates the main values for each parameter.
Abbreviations: AR, accumulation ratio; AUC, area under the curve; AUCtau, area under the curve for a dosing interval; AUCinf, area under the curve from time 0 to infinity; C, cohort; CL, clearance; Cmax/
Cmin, maximum/minimum concentration; n, number of patients for whom measurements were done; n.d., no data; t1/2, half-life; tmax, time to maximum concentration; VSS, volume of distribution in the
steady state.
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in the once-every-2-weeks scheme and infusion 3 in the
once-every-3-weeks scheme.
Half-life was calculated using three different approaches (in
the follow-up period, based on accumulation,13 and during
the dosing intervals). In all cohorts, a half-life of around
2 weeks was calculated during the follow-up periods (overall
median of all patients t1/2 follow-up 349 hours5 15 days) or
based on the accumulation ratio (overall median of all pa-
tients t1/2 effective 377 hours 5 16 days). A similar half-life
was calculated for cohort 7 over the dosing intervals of
3 weeks (overall median for cohort 7 was 374 hours 5
16 days). Generally, a lower half-life was calculated during
the shorter once-every-2-weeks dosing intervals for cohort 1
through cohort 6 (overall median for cohort 1 to cohort 6 and
combined dose 1 and dose 4 was 252 hours 5 11 days).
In general, no differences in PK results between males and
females were observed.
ADAs were detected in 20 of the 42 evaluable patients and
had no impact on the PK ofMP0250. The occurrence of ADAs
was independent of the MP0250 dose. In 2 of the 20 ADA-
positive patients, the titer ratio (titer sample post dose/titer
sample predose 1) was higher than 16. In one patient of
cohort 2 (1.5mg/kg, once every 2weeks, 3-hour infusion), the
titer ratio reached 256 (the highest observed value). This may
be related to a deviation from the study protocol in which this
patient did not have a filter in the infusion line during the first
MP0250 infusion. One patient of cohort 6 (8 mg/kg, once
every 2weeks, 1-hour infusion) showed amaximal titer ratio of
64 although this decreased at a later time point. Therewere no
apparent side effects associated with the presence of ADAs.
Pharmacodynamics
Binding of MP0250 to both its targets (VEGF-A and HGF) in
plasma was demonstrated. For VEGF, this was shown by a
reduction of plasma levels of free VEGF-A to undetectable for
the duration of treatment (Data Supplement), and for HGF, it
was shown by total plasma HGF levels increasing in a dose-
and time-dependent manner (Data Supplement). The in-
crease in total HGF corresponded to an increase in MP0250-
HGF complex in the circulation. Although the sample number
was small, it appeared that MP0250-HGF complex formation
might be plateauing around the dose of 4 mg/kg once every
2 weeks MP0250, thus possibly constituting the required
dose for a maximum effect of MP0250 on the HGF biology.
PIGF (placental growth factor) levels decreased transiently in
plasma after infusion of MP0250. There were no treatment-
related changes observed for plasma levels of VEGF-C,
angiopoietin-2, endoglin, fibroblast growth factor 2, inter-
leukin (IL)-6, IL-8 and IL-10, tumor necrosis factor a, soluble
VEGFR-2, ormatrixmetalloprotease 2 levels (data not shown).
Antitumor Activity
Among 40 patients evaluable for response, one patient
(3%) had an unconfirmed partial response (uPR), 24
patients (60%) had stable disease (SD), and 15 patients
(38%) had progressive disease.
The patient who had uPR had an anal cancer with lung
metastases. The patient had received two prior lines of
chemotherapy before entering into the trial. He received
one infusion of 12 mg/kg followed by an infusion of 8 mg/kg
once every 2 weeks and had PR at week 7 (30% reduction
in target lesions), followed by SD at a subsequent tumor
assessment with a time to progression of 23 weeks.
The median duration of SD was 18 weeks, with a maximum
of 72 weeks in one patient with salivary gland carcinoma,
who received MP0250 at the dose of 4 mg/kg (once every
2 weeks, 3-hour infusion).
The Kaplan-Meier analysis of progression-free survival
(PFS) resulted in an overall median PFS of 15.1 weeks.
Of the 39 patients with a postdose assessment of the sum of
longest diameters, 14 patients (36%) achieved some de-
gree of tumor shrinkage (Data Supplement).
























Cohort 1 (0.5 mg/kg)
Cohort 2 (1.5 mg/kg)
Cohort 3 (4 mg/kg)
Cohort 4 (8 mg/kg)
Cohort 5 (12 mg/kg)
FIG 2. Pharmacokinetic traces of MP0250. Plasma concentration versus time profiles of
cohorts 1-5 with once every 2 weeks dosing intervals. Numbers of patients per data point
vary due to different numbers of patients in each cohort and drop out of patients after
various periods (n 5 1-7, median, max/min). A dose level of 12 mg/kg in cohort 5 was
given to patients only for the first two cycles depicted in the graph.
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DISCUSSION
This study is the first clinical trial to evaluate the systemic
administration of a new class of drugs, DARPin molecules,
in patients with cancer. DARPin molecules are derived
from protein binding domains found in ankyrin repeat
proteins, a class of proteins widely used in nature for
activities ranging from simple anchoring of proteins to
enzyme inhibition.14 Binding domains with very high
specificity and affinity can be selected and used as
building blocks to create novel DARPin biologics that can
combine multiple mechanisms of action in one molecule.
MP0250 is a tri-specific molecule with four binding do-
mains: one each for VEGF and HGF and two for HSA;
albumin binding results in an extended plasma half-life,
and the specific binding and neutralization of VEGF and
HGF are responsible for therapeutic activity. The rationale
to inhibit the VEGF and HGF pathways simultaneously is
based on preclinical data that have shown that cMET can
be upregulated to overcome resistance to VEGF inhibition
and that simultaneous inhibition of these two pathways
can overcome treatment resistance.9,11,12
The predominant side effects of MP0250 observed in this
first-in-human study were hypertension and proteinuria,
both side effects that are characteristic of VEGF targeting
drugs.15-17 Both side effects were dose-related, which is
suggestive of an increasing inhibition of VEGF signaling with
increasing doses. Although grade 3 hypertension was re-
ported in about one-third of the patients, this AE was gen-
erally manageable and not treatment limited. Severe
proteinuria was reported at the highest tested dose and was
dose limiting in three patients (7%), and proteinuria
appeared on average after 2 months of therapy. This AE
warrants close monitoring in future clinical trials of MP0250,
and since dose interruption is required in some cases, this
should be reflected in the trial design. The dose of MP0250
to be used in combination studies could well be lower than
the single-agent recommended phase II dose, particularly
with other therapies that may have renal toxicities. With
respect to biochemical signs of HGF inhibition, hypo-
albuminemia, a class effect of HGF inhibitors, was frequently
observed.5 PD data also demonstrated that both compo-
nents of the DARPin molecule were active, resulting in a
reduction of circulating VEGF below the limit of detection as
well as a dose-proportional increase in HGF-MP0250
complexes. Thus, several pieces of data support the hy-
pothesis that both the VEGF targeting and the HGF targeting
components of MP0250 maintain their ability to bind and
inhibit their specific targets when administered to patients,
and the dose range tested here is highly relevant for the
MP0250 pharmacology. With the established recommended
doses for further studies, MP0250 can now be tested in
combination with other drugs to establish the role of con-
comitant VEGF/HGF inhibition as a potential remedy for
patients with adaptive resistance.
The PK of MP0250 showed a dose-proportional increase in
exposure (Cmax and AUC) and demonstrated a serum half-
life of approximately 2 weeks. Clearancewas lowwith a range
similar to values reported for therapeutic antibodies.18,19 The
half-life of 2 weeks is significantly longer than what would be
expected for a molecule in the size of MP0250 (65 kDa) and
indicates that themajority of the drug is bound as intended to
serum albumin. Consequently, convenient dosing intervals
of once every 2, 3, or even 4 weeks can be used, depending
on the combination therapy desired. No alteration in ex-
posure was observed in any patient.
Although conducted in a population of heavily pretreated
patients, this study demonstrated signs of single-agent ac-
tivity. One patient showed a uPR and over half of the patients
demonstrated stabilization of disease with the longest du-
ration of 72 weeks.
In summary, this is the first study that demonstrates that
rationally designed DARPinmolecules, a new class of agents
built on naturally occurring ankyrin repeat proteins, can be
safely administered to patients with cancer. The molecule,
MP0250, which contains three different components
addressing three different targets, showed clinical and PD
evidence that all intended targets are bound and that a si-
multaneous inhibition of VEGF and HGF is achieved. Based
on the results of the phase I study, MP0250 is currently in
phase II clinical evaluation in combination with bortezomib
and dexamethasone in patients with refractory multiple
myeloma20 (ClinicalTrials.gov identifier: NCT03136653).
Two additional DARPin drug candidates, MP0274, which
binds to two different epitopes of the HER2 receptor and is
capable of inducing apoptosis in HER2-expressing cell
models, and MP0310 (AMG 506), a molecule that is
designed to deliver 4-1BB activation to the tumor micro-
environment via binding to fibroblast activation protein, have
entered clinical testing (ClinicalTrials.gov identifiers:
NCT03084926 and NCT04049903, respectively).
In a first-in-human clinical trial, MP0250, a rationally
designed DARPin molecule, was found to have a man-
ageable safety profile and showed signs of clinical activity
supporting further clinical development especially in com-
bination therapies. Furthermore, the data provide evidence
that the DARPin platform could be a basis for a new class of
drugs in which specific properties can be combined in a
single molecule to provide innovative mechanisms of action.
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